Endo Oxymorphone ER Response To FDA “Approvable” Letter Expected In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will submit a new study, designed under FDA’s special protocol assessment procedures, in 250-300 opioid-naïve patients with chronic low back pain. Bias concerns raised about dropouts in other trials will be addressed through titration.
You may also be interested in...
Endo Oxymorphone ER Protocol Approved
Endo expects to submit a complete response to FDA's "approvable" letter for its extended-release oxymorphone "in early 2006.
Endo Oxymorphone ER Protocol Approved
Endo expects to submit a complete response to FDA's "approvable" letter for its extended-release oxymorphone "in early 2006.
Endo Oxymorphone Immediate-Release Study Cleared By FDA
Agency grants final approval to short-term, repeat-dose study of oxymorphone IR. FDA asks Endo to clarify aspects of its outcomes analysis for a new trial of an extended-release formulation prior to final approval of study protocol.